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DOTS: For More Than Just TB
Jeannette Gerry (BB/BBT), Selina Han (BME), Chietara Japutra (BC),
Molly Ott (BME), Andrea Rivas (BME)
Advisors: Prof. Jill Rulfs (BB/BBT), Prof. Helen Vassallo (School of Business)
Need:
Effective and uninterrupted treatment of Visceral 
Leishmaniasis in Brazil and African Trypanosomiasis in the 
Democratic Republic of the Congo (DRC)
What is DOTS?
Directly Observed Treatment Short course
• WHO recommended program to cure tuberculosis (TB)
• Focuses on patients adhering to treatment
• Minimizes drug resistance
• Huge investment in national healthcare 
• Highly efficient and cost-effective
• Cure rates of more than 85%
V. Leishmaniasis
Treatment:
• Oral Miltefosine
• 100mg/day, 4 weeks, for 
adults;
• 2.5mg/kg a day, 4 weeks, 
for children
• Cure rate almost 95%
• US$125-US$200 per 
treatment completion
A. Trypanosomiasis: 
1st line: 
• IV or IM pentamide 4mg/kg 
per day for 10 days
• >90% cure rate; cost is 
more than US$100 per 
treatment completion
2nd line: 
• IV melarsopropol 2.3mg/kg 
daily for 10 consecutive 
days
• 90%-95% cure rate; more 
than US$155 per patient
DOTS
Pros Cons
Strengthens healthcare system Potentially very expensive
(Solution: join forces with 
other stakeholders)
Linked with WHO's 1st Millennium 
Development Goal (eradicate
extreme hunger and poverty)
Stimulates economy Requires significant
government commitment
(Solution: work on public-private 
mix of healthcare providers)
Reduces development 
of drug resistance
Reduces rate of transmission 
and occurrence
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Approach: 
Implementing a modified DOTS protocol that pertains 
to Visceral Leishmaniasis and African Trypanosomiasis 
SUSTAINED COMMITMENT
• Political & financial commitment
DIAGNOSIS
• Case detection
• Blood test for AT & VL
• Skin test for VL
• Strengthen laboratory 
network
• Drug susceptibility tests
STANDARDIZED TREATMENTS
• Treatment services
• Supervision & patient support
• Improve access to treatment
DRUG SUPPLY & 
MANAGEMENT
• Uninterrupted, sustained, and 
quality assured drug supply
• Drug distribution system
• Drug cost minimization
• Drug use regulation
EVALUATION & IMPACT 
MEASUREMENT
• Recording and reporting system
• System sustainability
A. Trypanosomiasis in AfricaV. Leishmaniasis in Latin America
DOTS
Existent DOTS Initiatives
Brazil
• USAID & PAHO/Brazil (Pan American Health Organization)
• Nurse Supervisor Training Project: it ensures 
effective timely monitoring, evaluation and 
implementation of the disease
• Drugs for Neglected Diseases Initiative (DNDi) partnered 
with the Brazilian Ministry of Health 
• Combination therapy to reduce resistance
Democratic Republic of Congo
• USAID: In 2008, funds totaled almost $4.3 million in DRC
• Improving drug distributions
• Training health workers
• Strengthening lab network and capacity
V. Leishmaniasis A. Trypanosomiasis
What is it?
Disease caused by parasite
carried by sand flies
Disease caused by parasite
carried by tsetse flies
Incidence
200 million people at risk, 
500 000 cases/year
60 million people at risk, 
~60 000 cases/year
Location
Brazil is one of the 7
countries that account for 
>90% of global cases.
DRC had over 70% of all 
global cases (past 10 years)
A boy with V. Leishmaniasis Diagnosing A. Trypanosomiasis
DOTS PROCEDURE
Brazil
